Great Lakes Advisors LLC Takes $2.98 Million Position in Prestige Consumer Healthcare Inc. $PBH

Great Lakes Advisors LLC purchased a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 63,058 shares of the company's stock, valued at approximately $2,981,000. Great Lakes Advisors LLC owned about 0.13% of Prestige Consumer Healthcare at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of PBH. AQR Capital Management LLC raised its stake in shares of Prestige Consumer Healthcare by 11.9% during the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company's stock worth $2,558,000 after purchasing an additional 3,200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Prestige Consumer Healthcare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company's stock worth $2,535,000 after buying an additional 1,289 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Prestige Consumer Healthcare by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company's stock valued at $46,997,000 after acquiring an additional 120,965 shares in the last quarter. Jane Street Group LLC raised its position in Prestige Consumer Healthcare by 204.0% during the first quarter. Jane Street Group LLC now owns 104,802 shares of the company's stock valued at $9,010,000 after acquiring an additional 70,330 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its stake in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after acquiring an additional 269 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on PBH. Canaccord Genuity Group decreased their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating for the company in a research report on Friday, May 15th. Oppenheimer lowered shares of Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 14th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, June 25th. Finally, Zacks Research raised shares of Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a research report on Monday, August 10th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $70.75.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock opened at $50.59 on Friday. Prestige Consumer Healthcare Inc. has a 1-year low of $42.62 and a 1-year high of $71.07. The firm has a fifty day simple moving average of $49.65 and a 200-day simple moving average of $55.14. The company has a current ratio of 3.23, a quick ratio of 1.99 and a debt-to-equity ratio of 1.06. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of 14.17, a PEG ratio of 1.62 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.89 by $0.09. The firm had revenue of $265.71 million for the quarter, compared to the consensus estimate of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business's quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source